Quantcast

Latest Fabry Stories

2011-01-19 01:00:00

CARMIEL, Israel, Jan. 19, 2011 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-AMEX: PLX, TASE: PLX), announced today that management presented data on the Company's preclinical Fabry program and oral enzyme Gaucher program with experts in the field of lysosomal disorders at a Company-sponsored medical meeting which was recently held in New York City. The primary objective of the meeting was to discuss taliglucerase alfa, the Company's proprietary intravenously administered plant...

2010-10-29 05:55:00

CRANBURY, N.J., Oct. 29 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) will host a live conference call and webcast today, October 29, 2010 at 8:30 a.m. Eastern Time to discuss the Company's exclusive worldwide agreement with GlaxoSmithKline PLC to develop and commercialize Amigal (migalastat HCl) for the treatment of Fabry disease. Interested participants and investors may access the conference call today at 8:30 a.m. Eastern Time by dialing 877-303-5859 (U.S./Canada) or...

2010-02-24 06:18:00

CAMBRIDGE, Massachusetts, February 24, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces it has received Fast Track designation from the FDA for REPLAGAL(R) (agalsidase alfa), its enzyme replacement therapy for Fabry disease. Shire filed a BLA for REPLAGAL in December 2009. The FDA requested additional human pharmacokinetic data to confirm comparability between product that was manufactured in roller bottles,...

2009-10-22 14:46:01

A new study uses a creative structure-based remodeling strategy to design a therapeutic protein that exhibits significant advantages over currently available treatments for a rare disease that often leads to cardiac and renal failure. The research, published by Cell Press on October 22nd in the American Journal of Human Genetics, describes a new and highly promising candidate for enzyme replacement therapy (ERT) for Fabry disease. Fabry disease is a rare genetic disorder caused by a...

2008-07-21 18:00:18

CyGene Laboratories Inc. (OTC:CYGE) ("the Company") announced today that it is introducing StrokeScan(TM), a genetic screening test aimed at identifying high risk individuals who have a family history of stroke, cardiovascular or kidney disease. Offered at $499, StrokeScan(TM) analyzes genes that have been associated with the increased risk of stroke and the "alpha-galactosidase A" gene that is responsible for Fabry disease. Fabry disease is a genetic disorder that results in an enzyme...


Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'karpos', fruit.
Related